Britain and America have finalized a landmark bilateral deal that will keep zero tariffs on British drug products going into the American market.
The Terms of the Pact
As part of the deal, the UK has pledged to raise spending on drugs through the NHS. This move ensures that tariffs on these vital goods will be held at nothing for a timeframe of three years.
This development follows previous statements to hike duties on branded pharmaceutical imports, with figures discussed as high as one hundred percent.
"This arrangement between the United Kingdom bolsters the worldwide climate for cutting-edge drugs and introduces much-needed balance to U.S.–U.K. pharmaceutical trade," a release declared.
Commercial Significance
Medicines represent one of the the United Kingdom's biggest export categories to the US, which is by far the biggest market for large companies like GSK and AstraZeneca.
Export figures reveal that in the year prior to the third quarter, the UK sold medicines totaling £11.1bn to the US. This figure made up 17.4% of British export trade in that period.
"This agreement secures jobs, increases investment and sets the stage for the UK to become a global hub for life sciences," the Business and Trade Secretary commented.
Specific British Pledges
The pact includes several notable changes from the United Kingdom:
- Price Threshold Increase: The UK will lift the cost ceiling at which it considers new medicines to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to increase overall health service expenditure on treatments from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum manufacturers must pay back to the NHS to stay within budget will be capped at fifteen percent. In the past, rebates topped 20%.
Industry Background
This agreement takes place against a ongoing tension between the pharmaceutical industry and the UK government over spending levels and regulatory access.
The disagreement were intensified by claims that American consumers were charged significantly more for the same drugs than patients in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been delayed or cancelled, while major investments have been announced toward US facilities.
The Science Minister stated that the NHS had to spend more on drugs, noting that its spending on drugs had shrunk as a proportion of its total funding over the past decade.
